Nu­Cana stops Phase 2 as chemother­a­py de­riv­a­tive 'un­like­ly' to meet pri­ma­ry end­point

Chemother­a­py biotech Nu­Cana’s stock $NC­NA tanked near­ly 50% in pre­mar­ket trad­ing Fri­day fol­low­ing a Thurs­day an­nounce­ment that it had stopped a Phase 2 tri­al due …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER